0.52025-07-30https://www.a2m.nl/a2m/0.52025-07-30https://www.a2m.nl/services/0.52018-05-11https://www.a2m.nl/services/strategy/0.52020-09-27https://www.a2m.nl/services/market-access-and-reimbursement/0.52018-09-29https://www.a2m.nl/services/health-economic-modelling/0.52018-09-29https://www.a2m.nl/services/pricing-and-valuation/0.52018-10-03https://www.a2m.nl/services/biotechnology/0.52018-10-03https://www.a2m.nl/services/nutrition/0.52025-08-17https://www.a2m.nl/capabilities/0.52025-07-30https://www.a2m.nl/over-a2m/0.52024-08-09https://www.a2m.nl/publications/0.52025-07-30https://www.a2m.nl/bedankt/0.52019-04-11https://www.a2m.nl/helaas/0.52025-07-30https://www.a2m.nl/achievements/0.52025-07-30https://www.a2m.nl/contact/0.52025-07-30https://www.a2m.nl/an-innovative-pricing-model-to-assess-the-price-of-expensive-drugs-with-an-orphan-indication/0.52024-03-08https://www.a2m.nl/valuation-of-innovative-drugs/0.52024-05-09https://www.a2m.nl/valuation-of-innovative-drugs-ispor-atlanta-2024/0.52024-08-09https://www.a2m.nl/economic-insights-into-nutrition-unlocking-the-value-in-chronic-disease-management-ispor-atlanta-2024/0.52024-08-09https://www.a2m.nl/malnutrition-in-healthcare-treatment-pays-off/0.52025-08-19https://www.a2m.nl/a2m-blog/0.52025-08-17https://www.a2m.nl/masterclass-what-is-a-fair-price-for-medicines/0.52022-10-03https://www.a2m.nl/laatste-nieuwsbericht-1/0.52020-08-15https://www.a2m.nl/international-market-access-update/0.52020-08-15https://www.a2m.nl/economic-impact-of-macrosomia/0.52020-08-15https://www.a2m.nl/new-joint-publications-a2m-with-nestle-and-danone/0.52020-08-15https://www.a2m.nl/lecture-at-eurordis-in-paris/0.52020-08-15https://www.a2m.nl/annual-meeting-dgo-in-berlin/0.52020-08-15https://www.a2m.nl/eurordis-multi-stakeholder-symposium-in-brussels/0.52020-08-15https://www.a2m.nl/policy-consultancy-for-ministry-of-health-in-the-netherlands/0.52020-08-15https://www.a2m.nl/economics-of-obesity/0.52020-08-15https://www.a2m.nl/valuation-of-innovation/0.52020-08-15https://www.a2m.nl/valuation-tool-for-biotechnology/0.52020-08-15https://www.a2m.nl/presentation-of-nice-model-at-european-hematology-association/0.52020-08-15https://www.a2m.nl/formula-pharma-by-mark-jc-nuijtenworkinfo-a2m-partner-of-minerva-network-develops-multicountry-health-economic-models-for-its-clients-all-over-the-world-cost-effectiveness-models-and-budget-impact-models-the-models-by-a2m-successfully-contributed-to-positive-reimbursement-decisions-by-health-authorities-in-many-countries-read-more-notes-increasing-interest-in-our-pricing-model-and-algorithm-for-expensive-drugs-read-more-the-true-prices-of-drugs-read-more-de-echte-prijs-van-geneesmiddelen-read-more-a2m-minerva-in-vienna-at-ispor-read-more-ispor-vienna-read-more-evaluation-and-valuation-of-ultra-innovative-drugs-a-new-concept/0.52020-08-15https://www.a2m.nl/ispor-vienna/0.52020-08-15https://www.a2m.nl/a2m-minerva-in-vienna-at-ispor/0.52020-08-15https://www.a2m.nl/de-echte-prijs-van-geneesmiddelen/0.52020-08-15https://www.a2m.nl/the-true-prices-of-drugs/0.52020-08-15https://www.a2m.nl/increasing-interest-in-our-pricing-model-and-algorithm-for-expensive-drugs/0.52020-09-12https://www.a2m.nl/milestone-of-more-than-10000-views-on-our-policy-paper-challenging-the-icer/0.52020-11-27https://www.a2m.nl/guest-lecturer-for-colombian-american-chamber-of-commerce-on-drug-policy/0.52020-12-03https://www.a2m.nl/innovation-premium-for-innovative-orphan-drugs-in-oncology-and-rare-diseases/0.52021-04-24https://www.a2m.nl/mark-nuijten-epa-2021/0.52025-12-17https://www.a2m.nl/integrated-valuation-model-v4a2m-model/0.52025-12-17https://www.a2m.nl/valuation-of-innovative-drugs-at-ispor-2023-in-copenhagen/0.52024-08-09https://www.a2m.nl/malnutrition-in-healthcare-treatment-pays-off-1/0.52025-08-19https://www.a2m.nl/masterclass-what-is-a-fair-price-for-medicines-1/0.52017-10-24https://www.a2m.nl/ruud-bastianen/0.52017-10-24https://www.a2m.nl/mark-nuijten/